Stock analysts at Jefferies Group increased their target price on shares of MedAssets (NASDAQ:MDAS) from $25.00 to $30.00 in a report issued on Thursday, Stock Ratings Network reports. The firm currently has a “buy” rating on the stock. Jefferies Group’s price target suggests a potential upside of 30.27% from the company’s current price.
Shares of MedAssets (NASDAQ:MDAS) traded down 11.66% on Thursday, hitting $23.029. 2,916,745 shares of the company’s stock traded hands. MedAssets has a 1-year low of $15.40 and a 1-year high of $24.52. The stock’s 50-day moving average is $25.13 and its 200-day moving average is $21.09. The company has a market cap of $1.409 billion and a P/E ratio of 389.10.
MedAssets (NASDAQ:MDAS) last released its earnings data on Wednesday, October 30th. The company reported $0.31 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.30 by $0.01. The company had revenue of $166.40 million for the quarter, compared to the consensus estimate of $166.78 million. During the same quarter in the prior year, the company posted $0.32 earnings per share. The company’s quarterly revenue was up 1.8% on a year-over-year basis. On average, analysts predict that MedAssets will post $1.32 earnings per share for the current fiscal year.
A number of other analysts have also recently weighed in on MDAS. Analysts at FBR & Co. initiated coverage on shares of MedAssets in a research note to investors on Thursday. They set a “market perform” rating on the stock. Separately, analysts at FBR Capital Markets initiated coverage on shares of MedAssets in a research note to investors on Thursday. They set a “market perform” rating and a $24.00 price target on the stock. Finally, analysts at ISI Group downgraded shares of MedAssets from a “buy” rating to a “neutral” rating in a research note to investors on Thursday. They now have a $26.00 price target on the stock, down previously from $28.00. Eight equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $26.98.
In other MedAssets news, CAO Lance M. Culbreth unloaded 2,000 shares of the company’s stock on the open market in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $26.45, for a total value of $52,900.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
MedAssets, Inc (NASDAQ:MDAS) provides technology-enabled products and services.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.